RISS 학술연구정보서비스

검색
다국어 입력

http://chineseinput.net/에서 pinyin(병음)방식으로 중국어를 변환할 수 있습니다.

변환된 중국어를 복사하여 사용하시면 됩니다.

예시)
  • 中文 을 입력하시려면 zhongwen을 입력하시고 space를누르시면됩니다.
  • 北京 을 입력하시려면 beijing을 입력하시고 space를 누르시면 됩니다.
닫기
    인기검색어 순위 펼치기

    RISS 인기검색어

      검색결과 좁혀 보기

      선택해제

      오늘 본 자료

      • 오늘 본 자료가 없습니다.
      더보기
      • 무료
      • 기관 내 무료
      • 유료
      • KCI등재

        Anti-neoplastic cytotoxicity by complementary simultaneous selective “targeted” delivery for pulmonary adenocarcinoma: fludarabine-(5′-phosphoramidate)-[anti-IGF-1R] in dual-combination with dexamethasone-(C21-phosphoramidate)-[anti-EGFR]

        Cody P. Coyne,Lakshmi Narayanan 한국약제학회 2019 Journal of Pharmaceutical Investigation Vol.49 No.1

        Selective “targeted” delivery of chemotherapeutic agents represents a molecular strategy for achieving enhanced margins-ofsafety and greater potency compared to conventional small-molecular weight chemotherapeutics. Greater margins-of-safety are possible because extensive un-intentional diffusion of therapeutics across intact cell membranes of normal healthy cells residing within tissues and organ systems is minimized or avoided. Simultaneous, independent “targeted” delivery of one or more therapeutics at multiple sites on the external surface membrane of neoplastic cells has not been described extensively. Fludarabine-(5′-phosphoramidate)-[anti-IGF-1R] and dexamethasone-(C21-phosphoramidate)-[anti-EGFR] were synthesized by reacting fludarabine or dexamethasone-C21-monophosphate with a carbodiimide reagent and imidazole for synthesis of covalent fludarabine-(5′-phosphoramidate)-[anti-IGF-1R] and dexamethasone-(C21-phosphoramidate)-[anti- EGFR] immunopharmaceuticals. The pharmaceutical molar-incorporation-indexes for fludarabine-(C5-phosphoramidate)- [anti-IGF-1R] and dexamethasone-(C21-phosphoramidate)-[anti-EGFR] were 3.67:1 and 6.95:1 respectively. Simultaneous dual-combination selective “targeted” delivery with fludarabine-(5′-phosphoramidate)-[anti-IGF-1R] with dexamethasone-( C21-phosphoramidate)-[anti-EGFR] produced the most profound enhancement in anti-neoplastic cytotoxitity at the pharmaceutical-equivalent concentations of 10− 9 M (14.7% ± 0.80 SE) and 10− 8 M (54.0% ± 0.9 SE) respectively. Simultaneous dual “targeted” anti-neoplastic cytotoxicity can potentially be evoked ex-vivo and in-vivo with fludarabine- (5′-phosphoramidate)-[anti-IGF-1R] and dexamethasone-(C21-phosphoramidate)-[anti-EGFR] through the synergistic and additive efficacy achieved through the combined mechanisms-of-actions associated with; (1) covalently bound therapeutic moieties; (2) anti-trophic receptor IgG-immunoglobulin; and (3) activation of three host immune responses.

      연관 검색어 추천

      이 검색어로 많이 본 자료

      활용도 높은 자료

      해외이동버튼